OVERVIEW

Differentiated Pipeline of Single- and Dual Payload ADCs

We are at the forefront of next-generation ADCs and, through our cell-free platform, we have fully optimized the antibody, linker, and payload to expand the therapeutic window—minimizing toxicity and maximizing efficacy.

We are advancing multiple candidates in parallel to address large market opportunities. Our single-payload ADCs, STRO-004 and STRO-006, are designed with best-in-class potential for complex targets across multiple tumor types where competition remains limited. Our dual-payload ADC programs represent a new class of supercharged ADCs designed to overcome resistance and delay disease progression. By combining distinct payloads, these programs have the potential to deliver improved clinical benefit, tolerability, and durability of response.